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doi:10.1016/j.ejvs.2010.04.018Abstract Objectives: To determine the incidence of side effects following treatment of vari-
cose veins with carbon dioxideeoxygen (CO2/O2) foam sclerotherapy, and to compare results
with historical controls using CO2- or air-based foams.
Design: Cohort study with prospective data collection, private clinic setting.
Patients: The patient population consisted of one hundred patients, 95% women, age 52 SD 13
years-old, CEAP class C2EpAsPr.
Methods: Patients underwent ultrasound-guided foam sclerotherapy following thermal abla-
tion of saphenous trunks; 1e3% polidocanol and 70%CO2e30%O2 gas were mixed in a 1:4 propor-
tion. Volume injected averaged 22 SD 11 (range: 2e46) mL. Vital signs were monitored for 1 h;
side effects were recorded up to 24 h post treatment. Incidence of side effects was compared
to CO2- and air-based foam data.
Results: Heart rate decreased from 73 SD 11 at the start to 68 SD 9 bpm (p < 0.001, paired t-
test) following the procedure. Systolic and diastolic pressures, 127/75 SD 18/14 mmHg, respi-
ratory rate, 15 SD 4 rpm and pO2, 98 SD 2%, did not change significantly. Itching (7) or leg pain
(24) reporting was similar to that for air-based foam (pZ NS). Lack of reported chest tightness
and/or dry cough was superior to our previous data with CO2 or air foam (p < 0.05). Reporting
of dizziness (1) was less than that for air-based foam (p Z 0.002). The incidence of visual
disturbance (2%), was comparable with that for CO2 (3%) or air (8%) foam, but too few cases
were available for meaningful statistical analysis.son, MD, Morrison Vein Institute, 8575 East Princess, Drive Suite 223, Scottsdale, AZ 85255, USA.
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408 N. Morrison et al.Conclusions: Foam sclerotherapy using CO2/O2 foam was well tolerated by patients and re-
sulted in fewer side effects than similar treatment using air foams.
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Chemical ablation has become a valuable alternative for
the treatment of valvular insufficiency of the superficial
veins of the lower extremities.1e3 A wide range of venous
disease has been treated with ultrasound (US) guided foam
sclerotherapy (USGFS).4e16 Foam sclerotherapy can be
a primary treatment, or complementary to surgical treat-
ment or thermal ablation by radiofrequency or laser.
The gas used to prepare the foam may affect the
frequency of adverse reactions associated with the USGFS.
Air is used in a 4e1 ratio with a liquid sclerosant and
administration of foam volumes of less than 10 mL per
treatment session has been recommended.2 There is
evidence that larger volumes can be injected safely and
effectively if biocompatible gases (carbon dioxide, oxygen)
are employed to make the foam.1,17e19 In our personal
experience, the use of carbon dioxide (CO2) has reduced the
incidence of side effects or complications, as compared to
the use of air-based foam.1 This study investigated the inci-
dence of adverse events during CO2/O2 foam sclerotherapy.
Materials and methods
This study investigated the incidence of side effects and
complications of a CO2/O2-based foam. The results were
compared with previously published data for CO2- and air-
based foam sclerotherapy.1 The fundamental protocols were
similar for the three different types of gases used so far but
the data reported here do not comprise a randomised study.
Patient population
All subjects gave written informed consent for treatment
with polidocanol and for participation in a quality-assur-
ance research program. Initially, all patients had thermal
ablation of the great saphenous vein (GSV), performed
either with laser or radiofrequency energy. This treatment
also included ambulatory phlebectomy for the treatment of
varicose veins. 100 Patients with residual or recurrent
varices were treated by USGFS using CO2/O2-based scle-
rosant foam. Average patient age was 53 SD 13 (range
19e76) years. Women (n Z 95) outnumbered men (5). The
CEAP classification was C2EpAsPr for varicose veins,
primary aetiology, and saphenous reflux greater than 1 s.
Contraindications
Patients with known symptomatic patent foramen ovale
(PFO) were not treated. Patients with history of superficial
thrombophlebitis, multiple spontaneous abortions, family
history of thrombosis, previous deep venous thrombosis
underwent thrombophilia screening and were treated with
prophylactic low molecular weight heparin prior to thermal
or chemical ablation.Diagnostic ultrasound (US)
US was used for physiological and anatomical evaluation.20
The great, small, anterior and posterior accessory saphe-
nous veins were examined. Findings at the saphenofemoral
junction, proximal, mid and distal thigh, proximal, mid and
distal calf were summarised in a formal report. Out of
fascia tributaries and unusual veins were also evaluated.
Perforating, intersaphenous, Giacomini, and sciatic veins
were examined and noted if reflux was present. Reflux was
classified as lasting for 1 sec, 2 s, 3 s or longer than 4 s.
Ultrasound-guided foam sclerotherapy (USGFS)
Ultrasound evaluation identified residual incompetent
segments of the vein. A plan was then developed to a) close
recanalised segments of the treated GSV, b) expand abla-
tion distally into the GSV, c) ablate the SSV, d) close
incompetent tributaries and perforating veins, and e)
ablate remaining incompetent superficial veins.
Sclerosant foam preparation
The gas used in this study was a mixture of 70%CO2 and 30%
O2, supplied pre-mixed by the medical gas distributor. The
sclerosant used was 1e3% polidocanol, mixed with gas as
a 1:4 ratio. The Tessari dual syringe, three-way tap tech-
nique was employed to create the foam.21
Access
Direct puncture of incompetent veins was performed under
longitudinal or transverse ultrasound visualisation with
needle diameters of 0.4 mm (27G). Ultrasound imaging was
used to establish whether a further injection of foam was
needed for that segment. Injectionswere stopped once foam
approached a connection to the deep system. The GSV was
usually punctured in a residual segment in the calf. SSV and
tributary injection followed a distal-to-proximal approach.
Treatment of perforating veins was accomplished by indirect
injection into an extra-fascial tributary or saphenous vein
segment. Direct injection of perforating veins was avoided.
Table 1 summarises the veins that were treated. The diam-
eter of the treated veins averaged 2.5 SD 1.2 (range 1e6)
mm. Only one vein (10 mm) greater than 6 mm was treated.
2 mL of foam was used for most injections.
Patients were sometimes instructed to perform plantar
and dorsiflexion of the ankle to increase blood flow via the
deep veins and speed neutralisation of any foam that may
have reached the deep venous system. A total of 648 injec-
tions were performed in 176 legs, averaging 6.5 per patient,
or 3.7 per leg. Table 1 lists the number of injections per site.
The duration of treatment varied, lasting less than 15, 30,
and 45 min for 66%, 36% and 8% of the patients respectively.
The total foam volume injected per patient was 22 SD 11mL,
Table 1 Ultrasound-guided foam sclerotherapy of lower extremity veins as a complement to thermal ablation and
phlebectomy (N Z 100 patients).
Injection sites Number of injections Percentage
GSV tributaries distal to thigh 144 22.2%
GSV tributaries at mid thigh 106 16.4%
GSV tributaries at proximal thigh 105 16.2%
Distal GSV 75 11.6%
Distal SSV 61 9.4%
SSV tributaries 59 9.1%
Proximal SSV 54 8.3%
GSV at mid thigh 23 3.5%
Proximal GSV 18 2.8%
Perforating veins 3 0.5%
Total 648 100%
GSV: great saphenous vein; SSV: small saphenous vein.
2nd numbers is what I have in the data base.
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injected per leg was 12 SD 6, varying from 1 to 28 mL.
Patient monitoring
A registered nurse (RN) monitored vital signs pre-procedure,
every 15 min during the procedure, and 30 and 60 min post
procedure while the patient was still in the clinic. The vital
signs monitored were heart rate, blood pressure, respiratory
rate, pulse oximetry (pO2), and electrocardiogram.
Side effects or adverse events were also monitored
directly by the RN every 15 min during the procedure and 30
and 60 min post procedure. A telephone interview regis-
tered the events volunteered by the patients 2, 6 and 24 h
after the procedure. The expected sequelae monitored
were: injection site itching, localised leg pain, localised
burning sensation, tingling, and localised erythema. The
side effects sought after were dry cough, metallic taste,
and chest discomfort. The complications monitored
included respiratory difficulty, nausea, dizziness, cir-
cumoral paraesthesia, visual disturbance, and headache.
TTE and TCD monitoring
Transthoracic echocardiography (TTE) and transcranial
Doppler (TCD) were undertaken for those patients withTable 2 Vital signs associated with chemical ablation.
Ultrasound-guided foam sclerotherapy
Liquid: 1e3% polidocanol
Gas: 70% carbon dioxide (CO2)e30% oxygen (O2)
pre-procedure
Heart rate (bpm) 73 SD 11
Respiratory rate (rpm) 15 SD 4
Pulse oximetry (%) 78 SD 2
Systolic pressure (mmHg) 127 SD 18
Diastolic pressure (mmHg) 73 SD 14
a Significantly lower than pre-procedure heart rate (p < 0.001, pair
b Significantly lower than pre-procedure systolic pressure (p Z 0.04a history considered suspicious for right-to-left shunt, such
as patent foramen ovale (PFO). The aim was to assess the
presence of foam in the right and left heart and in the
middle cerebral arteries.22 Asymptomatic patients who
reported symptoms possibly attributable to a PFO, partic-
ularly migraine with aura, following the first injection
would undergo a PFO diagnostic protocol. Further foam
sclerotherapy was avoided in patients in whom a PFO was
found.Statistical analysis
Incidence of adverse events associated with CO2/O2 foam
were documented and compared with historical data
previously recorded for CO2 foam or air-based foams.
1 Data
are represented by the mean and standard deviation.
Paired t-tests of statistical significance were used to
compare ordinal data. Contingency table analysis was
undertaken using Chi-square tests.Results
There were no physiologically significant changes in vital
signs or electrocardiogram (Table 2). A 5 bpm heart rate
decrease at 60 min post procedure and a 2 mmHg decrease15 min into procedure 60 min post procedure
72 SD 10 68 SD 10a
14 SD 4 15 SD 3
78 SD 2 78 SD 2
125 SD 16b 126 SD 17
72 SD 12 73 SD 14
ed t-test).
3, paired t-test).
410 N. Morrison et al.in systolic pressure at 15 min into the procedure were
observed.
Localised itching was reported by 7 of the 100 patients,
a proportion similar to that reported by patients treated
with air- (6%, p Z NS) but less than that reported by
patients treated with CO2 (15%, p < 0.05). Localised leg
pain was reported by 24 patients, a proportion similar to
that reported after air- (22%, p Z NS) or CO2-based (20%,
p Z NS) USGFS. Two patients mentioned leg burning, two
mentioned tingling, one mentioned cramping, and one
complained of redness following CO2/O2-based USGFS.
Discomfort from compression stockings was mentioned by 5
patients.
No patient reported chest tightness or dry cough in this
series of 100 cases of USGFS using CO2/O2 gas (Table 3). This
finding was a significant improvement over air or CO2 foams
as previously reported (p< 0.05, chi squared). Dizziness was
reported once (1%), significantly less than the percentage
reported following air- (12%, pZ 0.002) but not statistically
different from CO2-based (3.1%, pZ NS) USGFS. The patient
reporting dizziness also reported headache, hangover, and
calf or ankle tingling, numbness and pain. The incidence of
visual disturbance was comparable with that observed with
CO2 and air foams (Table 3). However, the small number of
events observed in these series prevented meaningful
statistical comparison of these events.
Overall, 5 patients mentioned non-leg symptoms. One
patient mentioned earache and another mentioned
metallic/medicine tasting. There were two cases of visual
disturbance and one case of dizziness, headache and
hangover. All patients had received injections in proximal
tributaries, accounting for 8% (5/66) of patients who
received proximal tributary injections. Three of these 5
patients had injections in the proximal SSV, accounting for
7% (3/44) of patients who received proximal SSV injections.
One patient received bilateral proximal GSV injections,
accounting for 7% (1/14) of patients who received proximal
GSV injections. 36 Further patients who received more than
25 mL of foam reported no symptom of this type.Table 3 Side effects following chemical ablation.
Ultrasound-guided foam sclerotherapy
Liquid: 1e3% polidocanol
Gas: air or CO2 or 70%CO2e30%O2
Condition Gas
Air
Chest tightness 9 (18%)
Dry cough 8 (16%)
Dizziness 6 (12%)
Visual disturbance 4 (8.2%)
Metallic/medicine taste 0 (0%)
Nausea 2 (4%)
Circumoral paraesthesia 0 (0%)
Respiratory difficulty 0 (0%)
Total 49 (100%)
CO2: carbon dioxide.
O2: oxygen.
Adapted and expanded from Morrison et al. Comparisons of si
chemical ablation. J Vasc Surg 2008; 47:830e6.Discussion
Few reports describe the incidence and significance of side
effects following USGFS with the use of biocompatible
gases.1 This work makes a contribution toward an under-
standing of possible side effects following USGFS using
a physiological gas, CO2eO2, instead of air.
In controlled clinical trials, better efficacy of foam
compared to liquid sclerosant has been demonstrated.23e26
Pain, pigmentation or signs of inflammation, were more
common after foam than after liquid injection in one
report25 but other investigators noted no difference in
ecchymosis, inflammation or other side effects or adverse
reactions.23,24,26 Review papers have emphasised the
superiority of foam versus liquid sclerotherapy for the
treatment of patients with varicose veins.27,28 In our study
USGFS was complementary to thermal ablation by radio-
frequency or laser ablation.
One of the inspiring factors leading to the use of a physi-
ological gas-based foam was CO2 angiography.
29 Physiolog-
ical gas-based foam has been injected in larger volumes than
those usually recommended for air-based foam.19 A
commercially-prepared foam, composed primarily of CO2
and O2, produced smaller bubbles, and avoided arteriolar
obstruction (bubbles were seen with both foams, but did not
cause obstruction with the commercial product) caused by
the “home-made” air-based foam.30 CO2/O2-based foam is
more stable than pure CO2 based foam (Personal Communi-
cation: Tessari L, Cabrera A).
The European Consensus on Foam Sclerotherapy pub-
lished by Breu et al.2 made several recommendations based
on the opinions of experts, since little published data
existed at the time to address much of this subject.
Consensus statement 1 recommends accessing the great
saphenous vein at the proximal thigh. In our study, the
proximal great saphenous vein had already been ablated,
either surgically or thermally so we treated distal veins
first. In contrast to consensus 2, we initiated SSV injections
distally and found no disadvantage to this approach.CO2 CO2eO2
4 (3.1%) 0 (0%)
2 (1.6%) 0 (0%)
4 (3.1%) 1 (1%)
4 (3.1%) 2 (2%)
2 (1.6%) 1 (1%)
3 (2%) 0 (0%)
1 (0.8%) 0 (0%)
1 (0.8%) 0 (0%)
128 (100%) 100 (100%)
de effects using air and carbon dioxide foam for endovenous
Incidence of Side Effects Using Carbon DioxideeOxygen Foam 411Consensus 3 recommending indirect injections for treat-
ment of perforating veins was followed as was Consensus 4
recommending the dual-syringe technique for foam prepa-
ration. Consensus 5 mentioned air, and mixtures of CO2 and
O2 as gases to be used to prepare the foam. We have
reported the outcomes of these treatments above.
Consensus 6, recommending a 1:4 liquid-to-gas ratio was
followed. Consensus 7 recommended standardisation of
foam preparation for trials but not for daily practice. Our
quality-assurance program has been designed primarily for
daily clinical practice. Consensus 8 listed concentrations of
polidocanol according to specific clinical applications. Our
selection of 1% polidocanol matched our primary applica-
tion, treatment injection of tributary veins. Consensus 9
recommended maximum volumes per puncture up to 4 mL
for small saphenous and perforating veins, 6 mL for great
saphenous and tributary veins and up to 8 mL for recurrent
varicose veins. Yamaki et al. have indicated that multiple
small-dose injections of less than 0.5 mL can reduce the
passage of sclerosant foam into deep veins.31 We injected
CO2eO2 foam volumes of 2 mL or less. Consensus 10 and
consensus 11 recommended a maximum foam volume of
10 mL per leg or per session. Foam prepared with CO2
appears to be safe when injected in larger volumes.17e19,32
Our personal experience has indicated that side effects and
adverse reactions are not related to foam volume and may
occur with injections as little as 2 mL of foam.33,34.
Consensus 12 recommended use of more viscous foams,
such as 3% versus 1% polidocanol for large veins.35 The “3/1
study” demonstrated equivalent efficacy for 1% and 3%
polidocanol foam for sclerotherapy of GSV less than 8 mm in
diameter.36 In our present study polidocanol 1% was
appropriate for the treatment of 2e3 mm veins whichFigure 1 Transthoracic echocardiography and transcranial Dopp
transient signals (HITS) in the middle cerebral artery: a) four cham
following injection of foam sclerosant into peripheral leg vein; c)
patent foramen ovale into left atrium; and d) HITS in the middle ccomprised almost all the veins treated. According to
consensus 16, immediate compression of injected areas was
not performed, foam distribution was controlled by ultra-
sound, and ankle dorsiflexion was performed frequently.
Consensus 20 and 21 mentioned recommendations
regarding patent foramen ovale. Our philosophy has been
to monitor signs and symptoms early during the procedure
and to have ultrasound equipment available for TTE and
TCD evaluation. Evaluation for patent foramen ovale or
thrombophilia before USGFS was not routine. Consensus 23
regarding the use of prophylactic low molecular weight
heparin (LMWH) in selected patients was followed.
Consensus 24 and 25 regarding provision of patient infor-
mation on safety and efficacy and informed consent were
complied with. Consensus 26 and 27 related to ultrasound
guidance and interpretation criteria are routine in our
practice. Consensus 28 and 29 were not directly related to
this investigation; grading of results and thrombus removal
recommendations have been influential in our practice.
Our observations indicated that USGFS can be performed
safely. Neurological complications have been described37,38
but are rare and not exclusive to foam sclerotherapy; brain
infarct has occurred following saphenous vein stripping.39
Sylvoz et al. reported a case of polidocanol induced car-
diotoxicity after a 7 mL injection, and found 5 cases of
cardiac toxicity reported in the literature.40 Deep vein
occlusion has been reported at rates of 1.5% per treatment
session or approximately 3% per patient.41 We have inves-
tigated patients with duplicated femoral vein segments:
thrombosis was detected in 8.6% of the limbs or 12% of the
patients (5/43).42,43 Extensive, ascending thrombophlebitis
following foam sclerotherapy has been suggested as an
indication to investigate for malignancy.44ler demonstrating bubbles in the left heart and high intensity
ber view of heart; b) bubbles filling right atrium and ventricle
Bubbles (yellow arrow) progressing from right atrium through
erebral artery.
412 N. Morrison et al.Bubbles, not necessarily sclerosing foam,45,46 travel to
the deep system despite leg positioning, leg immobility, or
volume of foam injected. Bubbles consistently reach the
right chambers of the heart and may traverse to the left
chambers in patients with patent foramen ovale or right-to-
left pulmonary shunts (Fig. 1).22,47 HITS, commonly asso-
ciated with air embolisation, have been detected in the
middle cerebral artery with transcranial Doppler
(Fig. 1).33,34,43 The question pertinent to this investigation
is if the type of gas would influence the number of HITS.
This investigation demonstrated that USGFS using
a 70e30% gas mixture of CO2 and O2 is at least as safe as air-
based or CO2-based foams. Vital signs were not physiolog-
ically affected during the procedure. Leg symptoms were
no different from those seen with air foams but chest
tightness or dry cough was reduced in patients treated with
CO2eO2 foam. Visual disturbances were reported infre-
quently in this study but overall too few cases were
encountered for statistical analysis.
A word of caution is warranted regarding interpretation
of our findings. We have used historical data for comparison
and this was not a randomised study. Factors such as
patient education or awareness or even degree of internet
interaction could affect response to investigation of
symptoms. However, we compared results with the same
protocol for each of the patient cohorts included in the
analysis presented above.
In summary, USGFS with foam prepared using a physio-
logical mixture of carbon dioxide and oxygen was well
tolerated by virtually all patients, and resulted in fewer
side effects than in our historical data using air foam.
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